Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 401 to 450 of 903

TitleReference numberPublishedLast updated
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)TA749
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746
Nintedanib for treating progressive fibrosing interstitial lung diseasesTA747
Upadacitinib for treating moderate rheumatoid arthritisTA744
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)TA745
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapyTA736
Berotralstat for preventing recurrent attacks of hereditary angioedemaTA738
Tofacitinib for treating juvenile idiopathic arthritisTA735
Secukinumab for treating moderate to severe plaque psoriasis in children and young peopleTA734
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)TA732
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA733
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)TA730
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)TA731
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA726
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA727
Midostaurin for treating advanced systemic mastocytosisTA728
Sapropterin for treating hyperphenylalaninaemia in phenylketonuriaTA729
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Bimekizumab for treating moderate to severe plaque psoriasisTA723
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTA722
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndromeTA139
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphomaTA720
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)TA717
Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritisTA718
Secukinumab for treating active non-radiographic axial spondyloarthritisTA719
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA714
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Enzalutamide for treating hormone-sensitive metastatic prostate cancerTA712
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillationTA249
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillationTA256
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA275
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA355
Ravulizumab for treating atypical haemolytic uraemic syndromeTA710
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitisTA708
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancerTA707
Ozanimod for treating relapsing–remitting multiple sclerosisTA706
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesTA704
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)TA702
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)TA703
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)TA701
Ravulizumab for treating paroxysmal nocturnal haemoglobinuriaTA698
Ofatumumab for treating relapsing multiple sclerosisTA699

Results per page

  1. 10
  2. 25
  3. 50
  4. All